Equillium

Focus: Equillium is a monoclonal antibody-focused biotech company headquartered in La Jolla, CA, developing therapies across dermatology, respiratory, and immunology indications. The company operates at pre-revenue or early commercialization stage with a focused pipeline.

Dermatology Respiratory Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Equillium

AI assessmentNot Hiring

No open roles listed right now. Follow Equillium to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Itolizumab [Bmab 600]

Lupus Erythematosus

Phase 1

EQ001

Asthma

Phase 1

EQ001

Acute-graft-versus-host Disease

Help build intelligence for Equillium

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused mAb pipeline with Phase 3 programs (Itolizumab in GVHD, EQ001 in coronavirus) offering potential near-term value inflection
Multi-indication approach across high-unmet-need areas (alopecia areata, immunological disorders, respiratory) provides diverse technical exposure
Early-stage biotech environment enables broad cross-functional involvement and rapid skill development in monoclonal antibody development

Watch Out For

Zero active job openings at time of data collection signals potential hiring freeze or organizational constraint
Minimal public information on financials, funding, and employee count raises transparency concerns about stability and growth trajectory
Early-stage pipeline (mostly Phase 1/2) with only 2 active clinical trials creates execution risk and longer path to revenue

Generated by Claude from Equillium's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EQ101

Alopecia Areata

Phase 2

Clinical Trials (1)

NCT05589610Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

Phase 2

BNZ-1

Alopecia Areata

Phase 2

Clinical Trials (1)

NCT03532958Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Phase 2